Clinical trials: Salmonella Infections
Hepatitis A
Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity
To evaluate the immunogenicity, reactogenicity and safety of Hepatyrix when compared to the concomitant administration of Typherix and Havrix, and when compared to the administration of monovalent vaccines, Havrix or Typhim Vi.
- Trial name
- NCT00197249
- Testing
- Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix
- Volunteers
- 1,034 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Typhoid Fever
Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine
This study will evaluate a new (conjugate) vaccine for typhoid fever, which remains a serious disease especially difficult to treat in developing countries.
- Trial name
- NCT00277147
- Testing
- BB IND 6989
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Bloodstream Infection, Salmonella Bacteremia
Clinical Decision Support in Non-typhoidal Salmonella Bloodstream Infections in Children
In sub-Saharan Africa, non-typhoidal Salmonella (NTS) are a frequent cause of bloodstream infection, display high levels of antibiotic resistance and have a high case fatality rate (15%).
- Conditions
- Bloodstream Infection, Salmonella Bacteremia, Malaria,Falciparum, Severe Malaria
- Trial name
- DeNTS (NCT04473768)
- Where
- Belgium
- Volunteers
- 1,880 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Typhoid
Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine
This is a Multicenter, observer-blinded, randomized, Active controlled, Phase 3 study in healthy 6 months to 45 years aged Nepalese at the time of the first vaccine dose. The study objectives are: I.
- Trial name
- NCT03933098
- Testing
- Test Vaccine Vi-DT Typhoid conjugate, Control Vaccine Typbar TCV®
- Where
- 4 sites in Nepal
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Salmonella Typhi Infection
Understanding How Salmonella Typhi Infects Humans (Bottlenecks)
Typhoid fever is an infection caused by the bacteria Salmonella Typhi (S. Typhi). S. Typhi causes disease principally in developing countries where communities do not have access to safe water or adequate sanitation.
- Trial name
- NCT03889067
- Testing
- Salmonella Typhi challenge
- Where
- United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Inflammation, Vaccine
WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study
The purpose of this study is to determine if adding dietary fiber, such as inulin, to a diet that does not have enough fiber would raise the levels of potentially beneficial bacteria, such as Bifidobacterium, in the gut.
- Conditions
- Inflammation, Vaccine, Intestinal Permeability, Typhoid Fever
- Trial name
- NCT04543877
- Testing
- Inulin, Maltodextrin, Ty21a Typhoid Fever Vaccine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- USDA, Western Human Nutrition Research Center
Typhoid
Immunogenicity and Tolerability of Booster Typhoid Conjugate Vaccine (TCV) 5-6 Years After Initial Dose in Children in Burkina Faso
This study evaluated the persistence of immunity following primary typhoid conjugate vaccination in early childhood and assessed the immunogenicity and safety of a booster dose administered 5-6 years later.
- Trial name
- NCT07624175
- Testing
- Vi capsular polysaccharide-CRM197 conjugate vaccine (Vi-CRM), 0.5 mL IM
- Where
- Burkina Faso
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Kathleen Neuzil
Enteric Fever
Meropenem vs Azithromycin Efficacy in Case XDR Enteric Fever
1. Primary Objective: o To evaluate the efficacy of intravenous azithromycin compared with meropenem in the treatment of extensively drug-resistant (XDR) enteric fever. 2.
- Trial name
- NCT07314281
- Testing
- Azithromycin, Meropenem Injection
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- Indus Hospital and Health Network
Typhoid, Paratyphoid Fever
Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China
This study is part of International Vaccine Institute (IVI)'s typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries.
- Trial name
- NCT00131833
- Testing
- Typhoid Vi vaccine, Meningococcal A (control)
- Where
- China
- Volunteers
- 96,468 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid, Paratyphoid Fever
Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever
This study is part of the International Vaccine Institute's (IVI's) typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries.
- Trial name
- NCT00125008
- Testing
- Typhoid Vi vaccine, Hepatitis A vaccine
- Where
- India
- Volunteers
- 37,673 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Salmonella
Safety and Immunogenicity of CVD 1902 Oral Attenuated Vaccine to Prevent S. Paratyphi A Infection
The purpose of this study is to determine whether CVD 1902 (a live, attenuated, oral vaccine) is safe and effective in the prevention of Salmonella enterica serovar paratyphi A infection.
- Trial name
- NCT01129453
- Testing
- CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine
- Where
- 2 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Risk Reduction
Blood Donor CVD 5000
This is an open-label, non-randomized study. Volunteers will be vaccinated with the typhoid oral vaccine, Vivotif. Vivotif has been licensed by the Food and Drug Administration (FDA) for travelers to developing countries.
- Trial name
- NCT03971669
- Testing
- Vivotif Typhoid Oral Vaccine
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Typhoid Fever
Safety and Immunogenicity of Typhax, a Typhoid Vaccine
This was a randomized, double-blind, ascending dose study conducted at a single clinical research center.
- Trial name
- NCT03926455
- Testing
- Typhax (investigational typhoid fever candidate vaccine), Active Comparator Typhim Vi
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Matrivax Research and Development Corporation
Enteric Fever, Typhoid Fever
Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever
The investigators aim to compare two antibiotic treatments for enteric (typhoid) fever. Three hundred patients at Patan Hospital will be enrolled in the study.
- Trial name
- NCT01421693
- Testing
- Ceftriaxone, Gatifloxacin
- Where
- 2 sites in Nepal
- Volunteers
- 300 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Typhoid
Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso
Typhoid fever is an illness that may cause mild effects in children, such as fever and feeling tired, or it may cause serious effects-- even death.
- Trial name
- NCT03614533
- Testing
- Vi-Typhoid Conjugate Vaccine (Vi-TCV), Inactivated Poliovirus Vaccine (IPV)
- Where
- Burkina Faso
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Extensively Drug-Resistant Typhoid Fever, Typhoid Fever
This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intravenous Meropenem Combined With Oral Azithromycin in Children Aged 6 Months to Under 5 Years Diagnosed With Blood Culture-confirmed Extensively Drug-resistant Uncomplicated Typhoid Fever
This randomized controlled trial evaluates the comparative efficacy of intravenous meropenem alone versus intravenous meropenem combined with oral azithromycin in children aged 6 months to under 5 years diagnosed with blood…
- Conditions
- Extensively Drug-Resistant Typhoid Fever, Typhoid Fever, Salmonella Typhi Infection
- Trial name
- XDR-TY (NCT07445282)
- Testing
- Meropenem, Azithromycin + Metronidazole
- Where
- Pakistan
- Volunteers
- 90 people
- Sponsor
- Sheikh Zayed Medical College
Typhoid Fever
COMPARISON OF SINGLE VERSUS COMBINATION DRUG THERAPY IN EXTENSIVELY DRUG RESISTANT SALMONELLA TYPHI IN TERMS OF TIME TO DEFERVESCENCE
This randomized controlled trial will compare the effectiveness of single-drug therapy (meropenem) versus combination therapy (meropenem plus azithromycin) in children aged 2-16 years diagnosed with extensively drug-resistant…
- Trial name
- NCT07641348
- Testing
- meropenem, Meropenem and azithromycin combination
- Where
- Pakistan
- Volunteers
- 94 people
- Sponsor
- Iqra Asghar Ali
Typhoid Fever
Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants
This is an observer-blinded, comparative, single dose, clinical phase II/III study to assess the immunogenicity and safety of EuTCV compared to Typhoid conjugate vaccine in healthy Filipino participants aged 6 months to 45 years.
- Trial name
- NCT04830371
- Testing
- EuTCV (Vi-CRM Typhoid conjugate vaccine), Typbar-TCV
- Where
- 2 sites in Philippines
- Volunteers
- 444 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Typhoid Fever
Vellore Typhoid Vaccine Impact Trial
This cluster randomised trial will examine the impact of introducing TyphiBEV, a typhoid conjugate vaccine licensed in India, on the incidence of typhoid fever in a high burden urban setting in South India.
- Trial name
- VEVACT (NCT05500482)
- Testing
- Typhoid conjugate Vaccine
- Where
- India
- Volunteers
- 72,400 people, healthy volunteers welcome
- Sponsor
- Christian Medical College, Vellore, India